SCHEMBL345620

SCHEMBL345620

O=C1CCCc2c(-c3ccccc3)cc(-c3ccccc3)nc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
THRB P10828 1/20 0.48
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.44
MEN1 O00255 2/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPT P10636 5/20 0.43
POLB P06746 1/20 0.42
PKM P14618 1/20 0.42
RAB9A P51151 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
LMNA P02545 3/20 0.41
MAPK10 P53779 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10286837 0.85 KMT2A (0.48) KMT2AL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL527288 0.85 KMT2A (0.48) KMT2AL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL10286126 0.82 KMT2A (0.44) KMT2AL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL20081487 0.82 KMT2A (0.43) KMT2AL3MBTL1THRBKDM4EALDH1A1
SCHEMBL883090 0.81 KMT2A (0.45) KMT2AL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL883079 0.76 KMT2A (0.44) KMT2AL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL28902024 0.75 PDE4B (0.49) KMT2AL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL883086 0.74 KMT2A (0.53) KMT2AL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL14064439 0.74 THRB (0.44) KMT2ATHRBKDM4EALDH1A1MEN1
SCHEMBL10286170 0.73 KMT2A (0.41) KMT2AL3MBTL1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180102484-A1 NEW COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-04-12 US disclosed
US-20180102484-A1 NEW COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-04-12 US disclosed
US-9871206-B2 Compound, organic electroluminescence device material, organic electroluminescence device and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2018-01-16 US disclosed
EP-2072517-B1 Asymmetric phenanthrolins, method for their manufacture and doped organic semiconductor material containing them NOVALED GMBH (DE) 2015-01-21 EP disclosed
EP-2072517-B1 Asymmetric phenanthrolins, method for their manufacture and doped organic semiconductor material containing them NOVALED GMBH (DE) 2015-01-21 EP disclosed
US-20140309244-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-10-16 US disclosed
US-20140309244-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-10-16 US disclosed
US-20140162980-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES SYNGENTA CROP PROTECTION LLC (US) 2014-06-12 US disclosed
US-20140162980-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES SYNGENTA CROP PROTECTION LLC (US) 2014-06-12 US disclosed
WO-2013139822-A1 NOVEL BISOXIME MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2013-09-26 WO disclosed
EP-2194055-A1 Bridged pyridoquinazoline or phenanthroline compounds and organic semiconducting material comprising that compound Novaled AG (DE) 2010-06-09 EP disclosed
WO-2009083197-A2 ASYMMETRIC PHENANTHROLINES, PREPARATION PROCESS THEREFORE AND DOPED ORGANIC SEMICONDUCTOR MATERIAL CONTAINING THEM NOVALED AG (DE) 2009-07-09 WO disclosed
WO-2009083197-A2 ASYMMETRIC PHENANTHROLINES, PREPARATION PROCESS THEREFORE AND DOPED ORGANIC SEMICONDUCTOR MATERIAL CONTAINING THEM NOVALED AG (DE) 2009-07-09 WO disclosed
EP-2072517-A1 Asymmetric phenanthrolins, method for their manufacture and doped organic semiconductor material containing them Novaled AG (DE) 2009-06-24 EP disclosed
EP-2072517-A1 Asymmetric phenanthrolins, method for their manufacture and doped organic semiconductor material containing them Novaled AG (DE) 2009-06-24 EP disclosed
US-20080227979-A1 Pyrido[3,2-h]quinazolines and/or 5,6-dihydro derivatives thereof, a method for the production thereof and doped organic semiconductor material containing these NOVALED AG (DE) 2008-09-18 US disclosed
US-20080227979-A1 Pyrido[3,2-h]quinazolines and/or 5,6-dihydro derivatives thereof, a method for the production thereof and doped organic semiconductor material containing these NOVALED AG (DE) 2008-09-18 US disclosed
US-20080227979-A1 Pyrido[3,2-h]quinazolines and/or 5,6-dihydro derivatives thereof, a method for the production thereof and doped organic semiconductor material containing these NOVALED AG (DE) 2008-09-18 US disclosed
EP-1970371-A1 Pyrido(3,2-h)chinazolins and/or 5,6-Dihydro derivatives thereof, method for their manufacture and endowed organic semiconductor material containing them Novaled AG (DE) 2008-09-17 EP disclosed
EP-1970371-A1 Pyrido(3,2-h)chinazolins and/or 5,6-Dihydro derivatives thereof, method for their manufacture and endowed organic semiconductor material containing them Novaled AG (DE) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309244-A1 NOVEL MICROBIOCIDES MSR1, C3AR1, CD209 KMT2A 3934/4885L3MBTL1 1422/4885THRB 4735/4885
US-20080227979-A1 Pyrido[3,2-h]quinazolines and/or 5,6-dihydro derivatives thereof, a method for the production thereof and doped organic semiconductor material containing these PDXK, PNPO, QDPR KMT2A 1104/4885L3MBTL1 4319/4885THRB 4785/4885
US-20180102484-A1 NEW COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC DEVICE CBX8, MLX, HAX1 KMT2A 1095/4885L3MBTL1 2276/4885THRB 3988/4885
US-20140162980-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES PRDX4, PRDX6, DDT KMT2A 1798/4885L3MBTL1 773/4885THRB 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.